(Q39150764)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

metastatic renal cell carcinoma

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Giacomo Cartenì

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Mimma Rizzo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Clementina Savastano

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Giuseppe Di Lorenzo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Luigi De Lucia

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Luigi Maiorino

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Beniamino Casale

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Giuseppe Grimaldi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Roberta Formato

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Antonio Febbraro

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

language of work or name

English

0 references

publication date

31 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

219-224

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25078333%20AND%20SRC:MED&resulttype=core&format=json

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

mTOR signaling pathway and mTOR inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

Deconvoluting mTOR biology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

Targeting mTOR pathways in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

PI3K and mTOR signaling pathways in cancer: new data on targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

Targeted therapies for renal cell carcinoma: review of adverse event management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

Second-line therapy for refractory renal-cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

From randomized controlled trials to observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170

Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.170